This post was originally published by Cure Specific disease characteristics of, and treatments for, multiple myeloma were not associated with increased mortality risk in patients with multiple myeloma who developed COVID-19, according to data published in Journal of Hematology & Oncology. “Limited studies describing the impact of COVID-19 both in the (United States) and abroad suggest...Continue Reading

This post was originally published by Targeted Oncology C. Ola Landgren, MD, PhD, chief of Myeloma Service and hematologic oncologist at Memorial Sloan Kettering Cancer Center, discusses what is next for chimeric antigen receptor (CAR) T-cell therapy in the multiple myeloma landscape. Landgren thinks the field is about to reach its potential since there are several...Continue Reading

This article was originally published by OncLive In just the past 5 years, incredible progress has been made in multiple myeloma, evidenced by the emergence of novel CD38 antibodies, BCMA-directed treatments, and cereblon E3 ligase modulators (CELMoDs), according to Thomas G. Martin, MD. “We have a lot of options that are coming up. It’s really...Continue Reading